Director Health Economics and Outcomes Research
Daiichi Sankyo, Inc.
Dr. Dong Dai is a Director of Global HEOR and RWE at Daiichi Sankyo, Inc., leading the development and execution of HEOR and RWE strategies for specialty medicine products.
Prior to joining Daiichi Sankyo, Dong Dai was with Novartis where he was responsible for the development and execution of integrated HEOR evidence generation plan across the product life cycle leveraging clinical trial and real-world data. Before Novartis, Dong worked at IQVIA on HEOR and commercial solutions, and as a biostatistician for PPD.
Dong Dai graduated from Rutgers University with a PhD in Statistics and obtained an MBA from Drexel University.
